Australian Clinical Labs logo

Australian Clinical Labs(ASX) ACL

Market CapA$544.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+15%
5 Year-6%
1 Year+23%
1 Month+7%
A$2.91
-1.02%
-0.03Today
Australian Clinical Labs last closing stock price
MetricPriceDate
Last closeAUD 2.912026-10-12
Australian Clinical Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.56%AUD 2.812026-10-05
1 month+6.59%AUD 2.732026-09-11
3 month+31.42%AUD 2.212026-07-14
Year to date+11.37%AUD 2.612025-12-31
1 year+23.49%AUD 2.362025-10-10
3 year+20.09%AUD 2.422023-10-13
5 year-6.18%AUD 3.102021-10-13
Since inception+15.03%AUD 2.562021-05-14

Australian Clinical Labs Financials at a Glance

Market Cap

A$544.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$1.47B

Net Income (TTM)

A$56.14M

EPS (TTM)

A$0.12

P/E Ratio

23.79

Dividend

A$0.13

Beta (Volatility)

0.11 (Low)

Price

A$2.91

Volume

123,921

Open

A$2.95

Previous Close

A$2.91

Daily Range

A$2.90 - A$2.95

52-Week Range

A$1.83 - A$3.03

Estimated Earnings Date

Feb 23, 2027

ACL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Australian Clinical Labs

Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company provides essential services to both private and public hospitals, focusing on advanced molecular genetics and comprehensive pathology analyses.

Products and Services
  • Standard and advanced diagnostic pathology services
  • Genetic carrier screening and infectious molecular testing
  • Comprehensive serology, microbiology, and cardiac diagnostic assessments
Growth Outlook
  • Revenue of AUD 368 million in the latest quarter, showing strong demand
  • Consistent growth in gross profit margin, reaching 22.1% in Q4 2026
  • Expansion into new markets and services expected to drive future growth
Financial Highlights
  • Net income of AUD 18.1 million reported for Q4 2026
  • Trailing twelve months (TTM) revenue of AUD 1.4 billion, indicating robust performance
  • Dividend yield of 4.67%, reflecting commitment to shareholder returns
Australian Clinical Labs Limited has established itself as a key player in the medical diagnostics and research sector. The company’s extensive portfolio includes both standard examinations and advanced molecular genetics, catering to a wide range of healthcare needs. With a focus on innovation and quality, ACL is well-positioned to capitalize on the growing demand for diagnostic services in Australia. The growth outlook remains positive, supported by recent revenue trends and an expanding service offering. The company’s financial performance has shown resilience, with a notable increase in net income and a strong gross profit margin. The commitment to returning value to shareholders is evident through a competitive dividend yield. Investors may find Australian Clinical Labs Limited an attractive opportunity within the healthcare sector, given its solid financial foundation and growth potential. The company’s strategic initiatives and market positioning suggest a promising future in the evolving landscape of medical diagnostics.
AI Generated • Sep 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

4,500

CEO

Greg Horan

Website

www.clinicallabs.com.au

Headquarters

Clayton, VIC 3168, AU

ACL Financials

Key Financial Metrics (TTM)

Gross Margin

20.59%

Operating Margin

8.04%

Net Income Margin

3.25%

Return on Equity

15.80%

Return on Capital

12.63%

Return on Assets

4.00%

Earnings Yield

4.20%

Dividend Yield

4.42%

Payout Ratio

1.04%

Stock Overview

Market Cap

A$544.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

185.05M

Volume

123.92K

Avg. Volume

668.02K

Financials (TTM)

Gross Profit

A$421.07M

Operating Income

A$329.50M

EBITDA

A$398.03M

Operating Cash Flow

A$346.11M

Capital Expenditure

-A$17.99M

Free Cash Flow

A$328.12M

Cash & ST Invst.

A$25.66M

Total Debt

A$337.41M

Australian Clinical Labs Performance Analysis

Australian Clinical Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 692,103,000-30.0%
20242024-06-30AUD 689,728,000-0.3%
20252025-06-30AUD 736,148,0006.7%
20262026-06-30AUD 729,522,000-0.9%
Australian Clinical Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-312.8%
Q42025-06-300.8%
Q22025-12-31-2.9%
Q42026-06-301.8%
Australian Clinical Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 0.18-79.8%
20242024-06-30AUD 0.12-32.8%
20252025-06-30AUD 0.1742.1%
20262026-06-30AUD 0.12-27.7%
Australian Clinical Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-39.3%
Q42025-06-30107.3%
Q22025-12-31-76.2%
Q42026-06-30231.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$368.10M

+2.5%

Gross Profit

A$81.45M

-40.1%

Gross Margin

22.13%

N/A

Market Cap

A$544.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$120.90K

N/A

Employees

4,500

N/A

Net Income

A$18.14M

-4.4%

EBITDA

A$107.59M

+3.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$25.66M

-4.4%

Total Debt

A$337.41M

+9.2%

Accounts Receivable

A$67.45M

-17.2%

Inventory

A$14.25M

-15.3%

Long Term Debt

A$229.00M

+12.2%

Short Term Debt

A$108.40M

+3.5%

Return on Assets

4.00%

N/A

Return on Invested Capital

15.32%

N/A

Free Cash Flow

A$94.33M

+13.1%

Operating Cash Flow

A$100.44M

+16.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLS.AXHealius Limited
A$0.39+0.00%
CTE.AXCryosite Limited
A$1.21+0.00%
BDX.AXBCAL Diagnostics Limited
A$0.09+1.11%
RHY.AXRhythm Biosciences Limited
A$0.08+1.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.39+1.78%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$139.76-1.94%
IRENIren
$35.19-1.46%
NOKNokia
$10.36+2.17%

Questions About ACL

What is the current price of Australian Clinical Labs?

Australian Clinical Labs is trading at A$2.91 per share.

What is the 52-week range for Australian Clinical Labs?

Over the past 52 weeks, Australian Clinical Labs has traded between A$1.83 and A$3.03.

How much debt does Australian Clinical Labs have?

As of the most recent reporting period, Australian Clinical Labs reported total debt of A$337.41M.

How much cash does Australian Clinical Labs have on hand?

Australian Clinical Labs reported A$24.73M in cash and cash equivalents in its most recent financial results.

What is Australian Clinical Labs’s dividend yield?

Australian Clinical Labs currently has a dividend yield of 4.42%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services